Holen Sie sich die Stockscreener-App
4.72
0.21%
-0.01
Handel nachbörslich:
4.65
-0.07
-1.48%
Lifecore Biomedical Inc Aktie (LFCR) Neueste Nachrichten
Avoiding Lag: Real-Time Signals in (LFCR) Movement - Stock Traders Daily
Lifecore Biomedical (LFCR) Q2 2026 Earnings Call Transcript - AOL.com
Judge approves $3.75 million Lifecore investor settlement - minnlawyer.com
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Lifecore - TMX Newsfile
Lifecore Biomedical Reports Financial Results for the Second Quarter Ended June 30, 2026, and Provides Corporate Update - marketscreener.com
Lifecore Biomedical, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Discipline and Rules-Based Execution in LFCR Response - news.stocktradersdaily.com
Earnings call transcript: Lifecore Biomedical tops revenue view in Q2 2026 - Investing.com Canada
Lifecore Biomedical (NASDAQ:LFCR) Releases Quarterly Earnings Results, Beats Estimates By $0.03 EPS - MarketBeat
Transcript : Lifecore Biomedical, Inc., Q2 2026 Earnings Call, Aug 05, 2026 - marketscreener.com
Lifecore Biomedical, Inc. Reaffirms Earnings Guidance for the Calendar Year 2026 - marketscreener.com
Lifecore Biomedical, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Lifecore Biomedical Q2 Earnings Call Highlights - marketbeat.com
Lifecore Biomedical, Inc. (LFCR) Q2 FY2026 earnings call transcript - Yahoo Finance
LFCR: Q2 revenue fell 6.2% to $34.2M, but new business wins and guidance reaffirmed - TradingView
Lifecore Biomedical Backs 2026 Adj EBITDA of $20.5M-$25M >LFCR - Moomoo
Lifecore Biomedical Q2 revenue falls to $34.2 million as loss widens - Quiver Quantitative
Lifecore Biomedical 2026: Revenue $34.17M, EPS ($0.19) — 10-Q Summary - TradingView
Lifecore Biomedical: Q2 Earnings Snapshot - marketscreener.com
Lifecore Biomedical (NASDAQ: LFCR) Q2 revenue slips as 2026 guidance reaffirmed - Stock Titan
Press Release: Lifecore Biomedical Reports Financial Results for the Second Quarter Ended June 30, 2026, and Provides Corporate Update - moomoo.com
LFCR: Q2 2026 delivered strong revenue, margin expansion, and robust pipeline growth - TradingView
Lifecore Biomedical Q2 FY26 net loss widens to $6.2 million; revenue falls 6.2% to $34.2 million - Bitget
Lifecore Biomedical Inc expected to post a loss of 22 cents a shareEarnings Preview - TradingView
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Lifecore - TMX Newsfile
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Lifecore - TMX Newsfile
Zacks Research Upgrades Lifecore Biomedical (NASDAQ:LFCR) to Hold - marketbeat.com
Lifecore Biomedical to Report Financial Results for the Second Quarter Ended June 30, 2026, on August 5, 2026 - GlobeNewswire
Lifecore Sets Aug. 5 Webcast for Second-Quarter Results - Stock Titan
Lifecore Biomedical (LFCR) Tests Resistance After a Modest UptickBull Flag - dars.gov.et
Lifecore Biomedical signs three new customer de... - Pluang
Lifecore Biomedical Signs Three New Customer Agreements - The Manila Times
Lifecore Biomedical Announces Three New Customer Agreements Spanning Late-Stage Regenerative Medicine and Early-Stage Development Programs - Quiver Quantitative
Regenerative Medicine and Device Programs Expand Lifecore’s Pipeline - Stock Titan
Lifecore Biomedical Inc (LFCR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Lifecore Biomedical Inc (LFCR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Lifecore Biomedical Inc (LFCR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
LFCR|Lifecore Biomedical Inc|Price:4.330|Chg%:-0.100 - TradingKey
Lifecore Biomedical Inc (LFCR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Lifecore Biomedical (LFCR) Slips 2.26% as Stock Tests Key Support Near $4.11Defined Outcome ETF - dars.gov.et
Bronstein, Gewirtz & Grossman, LLC Encourages Lifecore Biomedical - The National Law Review
Lifecore Biomedical, Inc. Revenue Breakdown – NASDAQ:LFCR - TradingView
Lifecore Biomedical (LFCR) Pulls Back: Testing Key Support After 2.26% DeclineNegative Gamma - dars.gov.et
Lifecore Biomedical Inc. (LFCR) Q1 2026 Earnings: EPS Misses Estimates by Wide Margin Amid Operational ChallengesBook Value Growth - dars.gov.et
LFCR|Lifecore Biomedical Inc|Price:4.340|Chg%:+0.010 - TradingKey
Lifecore Biomedical (LFCR) Q1 2026 earnings summary - Quartr
Lifecore Biomedical (LFCR) Proxy filing Summary - Quartr
LFCR Deadline: LFCR Investors Have Opportunity to Lead Lifecore Biomedical, Inc. Securities Fraud Lawsuit - GuruFocus
Lifecore Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Sahm
What Triggered Lifecore Biomedical's Recent Stock Plunge - Kavout | AI
New Lifecore Hire Gets 3,500 Stock Units Vesting in Three Years - Stock Titan
Lifecore Biomedical Inc (LFCR) Continues Winning Contracts, Ignored by the Market - Yahoo Finance
Lifecore Biomedical (LFCR) AGM 2026 Summary - Quartr
Lifecore Biomedical (LFCR) Q2 2024 earnings summary - Quartr
Lifecore Biomedical (LFCR) Q3 2024 earnings summary - Quartr
Lifecore Biomedical Inc. (LFCR) Q1 2026 Earnings: Deep EPS Miss Highlights Operational DifficultiesFull Year Guidance - dars.gov.et
LFCR Q1 2026 Earnings: EPS Misses Estimates, Stock DeclinesFinancial Summary - dars.gov.et
Lifecore Biomedical Inc. (LFCR) Drops Nearly 6% as Stock Tests Key Support LevelsFloat Adjusted Cap - dars.gov.et
Lifecore Biomedical (LFCR) Slips 3.17%: Testing Key Support at $4.65WMA Signal - dars.gov.et
LFCR Q1 2026 Earnings: EPS Misses Estimates Amid Operational ChallengesGross Profit Margin - dars.gov.et
LFCR Q1 2026 Earnings: EPS Misses Estimates by Wide Margin, Revenue Not DisclosedEarnings Risk Report - DonanımHaber
0.79%
5.15%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):